Department of General Surgery, Pendik Education and Research Hospital, Faculty of Medicine, Marmara University, 34899, Pendik, Istanbul, Turkey.
Department of Pathology, Pendik Education and Research Hospital, Faculty of Medicine, Marmara University, 34899, Pendik, Istanbul, Turkey.
Langenbecks Arch Surg. 2023 May 25;408(1):210. doi: 10.1007/s00423-023-02930-4.
The optimal waiting period after neoadjuvant treatment in patients with locally advanced rectal cancers is still controversial. The literature has different results regarding the effect of waiting periods on clinical and oncological outcomes. We aimed to investigate the effects of these different waiting periods on clinical, pathological, and oncological outcomes.
Between January 2014 and December 2018, a total of 139 consecutive patients with locally advanced rectal adenocarcinoma, who were treated in the Department of General Surgery at the Marmara University Pendik Training and Research Hospital, were enrolled in the study. The patients were split into three groups according to waiting time for surgery after neoadjuvant treatment: group 1 (n = 51) included patients that have 7 weeks and less (≤ 7 weeks) time interval, group 2 (n = 45) 8 to 10 weeks (8-10 weeks), group 3 (n = 43) 11 weeks and above (11 weeks ≤). Their database records, which were entered prospectively, were analyzed retrospectively.
There were 83 (59.7%) males and 56 (40.3%) females. The median age was 60 years, and there was no statistical difference between the groups regarding age, gender, BMI, ASA score, ECOG performance score, tumor location, and preoperative CEA values. Also, we found no significant differences regarding operation times, intraoperative bleeding, length of hospital stay, and postoperative complications. According to the Clavien-Dindo (CD) classification, severe early postoperative complications (CD 3 and above) were observed in 9 patients. The complete pathological response (pCR, ypT0N0) was observed in 21 (15.1%) patients. The groups had no significant difference regarding 3-year disease-free and 3-year overall survival (p = 0.3, p = 0.8, respectively). Local recurrence was observed in 12 of 139 (8.6%) patients and distant metastases occurred in 30 of 139 (21.5%) patients during the follow-up period. There was no significant difference between the groups in terms of both local recurrence and distant metastasis (p = 0.98, p = 0.43, respectively).
The optimal time for postoperative complications and sphincter-preserving surgery in patients with locally advanced rectal cancer is 8-10 weeks. The different waiting periods do not affect disease-free and overall survival. While long-term waiting time does not make a difference in pathological complete response rates, it negatively affects the TME quality rate.
局部晚期直肠癌患者新辅助治疗后的最佳等待时间仍存在争议。文献对等待时间对临床和肿瘤学结果的影响有不同的结果。我们旨在研究这些不同的等待时间对临床、病理和肿瘤学结果的影响。
2014 年 1 月至 2018 年 12 月,共有 139 例局部晚期直肠腺癌患者在马尔马拉大学彭迪克培训与研究医院普外科接受治疗,纳入本研究。根据新辅助治疗后手术的等待时间,患者被分为三组:组 1(n = 51)包括≤7 周的患者,组 2(n = 45)为 8-10 周,组 3(n = 43)为 11 周及以上。他们的数据库记录是前瞻性输入的,然后进行回顾性分析。
男性 83 例(59.7%),女性 56 例(40.3%)。中位年龄为 60 岁,三组在年龄、性别、BMI、ASA 评分、ECOG 表现评分、肿瘤位置和术前 CEA 值方面无统计学差异。此外,我们发现手术时间、术中出血量、住院时间和术后并发症之间也没有显著差异。根据 Clavien-Dindo(CD)分类,9 例患者发生严重早期术后并发症(CD 3 级及以上)。21 例(15.1%)患者完全病理缓解(ypT0N0)。三组在 3 年无病生存率和 3 年总生存率方面无显著差异(p = 0.3,p = 0.8)。随访期间,139 例患者中有 12 例(8.6%)发生局部复发,30 例(21.5%)发生远处转移。三组在局部复发和远处转移方面无显著差异(p = 0.98,p = 0.43)。
局部晚期直肠癌患者术后并发症和保留括约肌手术的最佳时间为 8-10 周。不同的等待时间不会影响无病生存率和总生存率。虽然长期等待时间对病理完全缓解率没有影响,但会对 TME 质量率产生负面影响。